MedTrace Logo

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

NCT04527900 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-06-19

No results posted yet for this study

Summary

A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced Endometrial Cancer is non-inferior to the historic compliance rate of the chemoradiation arm of GOG 258 study

Conditions

Interventions

DRUG

carboplatin and paclitaxel

carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)

RADIATION

pelvic IMPT (Intensity Modulated Proton Therapy)

whole pelvis will receive a total dose of 4500 cGy in 25 fractions to 5040 cGy in 28 fractions

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Pranshu Mohindra, MD · University of Maryland/Maryland Proton Treatment Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2024-07-02
Completion
2024-07-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527900 on ClinicalTrials.gov